AFP and liver cancer: To target high risk individuals with liver cancer, screening follows a two-stage protocol: (1) initial screening identifies high-risk individuals through HBsAg testing for viral hepatitis infection; (2) primary surveillance for high-risk cohorts employs semi-annual ultrasonography (US) combined with alpha-fetoprotein (AFP) testing.